Breakpoint to Present At Tumour Models London Summit

Breakpoint’s Managing Director Jon Hollick will present a talk entitled “Decoding DNA Damage Response (DDR) Efficacy in Tumour Models to Advance Translation into the Clinic” at the 12th Annual Tumour Models  London Summit (06-07 December 2023). He will also participate in the opening plenary panel discussing “How Do You Select the Best Model for Your […]

Breakpoint To Present At LSX Inv€$tival Showcase

Breakpoint’s Managing Director Jon Hollick will present a company overview at the LSX Inv€$tival Showcase in London on November 13, 2023.

Breakpoint To Present At BIO Investor Forum

Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO Investor Forum in San Francisco on October 18, 2023. 10:00am, Franciscan C.

Breakpoint To Present At BIO International Convention 2023

Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO International Convention in Boston on June 7, 2023. 12:15pm, Session Room 104A.

Breakpoint To Present At DDR Inhibitors Summit, 2023

Breakpoint’s Managing Director and Head of Research Jon Hollick will give a talk entitled “Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold” at the DDR Inhibitors Summit in Boston, 24-26 January 2023.

BVF Partners L.P. Joins Breakpoint’s Investor Syndicate

Biotechnology Value Fund (BVF Partners), a San Francisco-based private investment partnership, has contributed capital in an extension of Breakpoint Therapeutics’ last funding round. Gorjan Hrustanovic, Managing Director at BVF Partners, will join Breakpoint’s Advisory Board as an Observer.

Dr. Juan Jaen Joins Breakpoint’s Advisory Board

Breakpoint welcomed Dr. Juan Jaen to its Advisory Board, adding his nearly 40 years of experience at the forefront of drug discovery and development to the company’s resources. He is Co-Founder, President, and member of the Board of Directors of Arcus Biosciences. Prior to founding Arcus, Juan was Co-Founder of Flexus Biosciences and before that […]

Evotec and venture capital consortium form “Breakpoint Therapeutics GmbH”

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers.